UNASSIGNED: Despite the dramatic improvements achieved in @entity5 treatment through a better understanding of the @entity5 biology, @entity43 is still characterized by a poor prognosis: most @entity1 diagnosed with this disease will ultimately die from it. In various clinical trials conducted over a time span of two decades, new combinations of conventional chemotherapy regimens have failed to achieve significant improvements in oncologic outcome in @entity43 @entity1 . We have now entered an era of "personalized medicine" in which new medications are designed to specifically target molecular pathways involved in @entity105 and @entity5 progression. Encouraging results in different @entity5 types have been reported, applying an increasing number of target therapies that are still under evaluation. In this setting, one of the most successfully targeted molecular pathways is @entity5 angiogenesis. Bevacizumab, a monoclonal antibody binding @entity7 ( @entity7 ), has been recently incorporated in the treatment of primary and recurrent @entity43 @entity1 after multiple phase III randomized controlled trials have proven its clinical benefit. Based on these positive results, more anti-angiogenic molecules using different mechanisms of action have been developed and are currently under investigation. Among these molecules, the @entity4149 kinases inhibitors are probably the most promising ones. @entity19977 is a @entity4149 kinase inhibitor targeting @entity7 receptors that has been tested in various trials with promising results. The aim of this manuscript is to review the current role of @entity19977 in the treatment of @entity43 and to present an overview of the ongoing clinical trials in this setting.

Cediranib in XXXX : state of the art and future perspectives.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity19977 :: ('MESH:C500926', 'Chemical') :: ['Cediranib', 'cediranib'] @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']
